FR2792837B1 - MEDICINES USEFUL FOR THE TREATMENT OF ADIPOSE MASS REGULATION DISORDERS AND DISEASES ASSOCIATED WITH LEPTIN PRODUCTION DISORDERS - Google Patents

MEDICINES USEFUL FOR THE TREATMENT OF ADIPOSE MASS REGULATION DISORDERS AND DISEASES ASSOCIATED WITH LEPTIN PRODUCTION DISORDERS

Info

Publication number
FR2792837B1
FR2792837B1 FR9905450A FR9905450A FR2792837B1 FR 2792837 B1 FR2792837 B1 FR 2792837B1 FR 9905450 A FR9905450 A FR 9905450A FR 9905450 A FR9905450 A FR 9905450A FR 2792837 B1 FR2792837 B1 FR 2792837B1
Authority
FR
France
Prior art keywords
disorders
treatment
diseases associated
adipose mass
leptin production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9905450A
Other languages
French (fr)
Other versions
FR2792837A1 (en
Inventor
Cinderella Gerhardt
Romero Ignacio Andres Romero
Arthur Donny Strosberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9905450A priority Critical patent/FR2792837B1/en
Priority to PCT/FR2000/001171 priority patent/WO2000066149A1/en
Publication of FR2792837A1 publication Critical patent/FR2792837A1/en
Application granted granted Critical
Publication of FR2792837B1 publication Critical patent/FR2792837B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
FR9905450A 1999-04-29 1999-04-29 MEDICINES USEFUL FOR THE TREATMENT OF ADIPOSE MASS REGULATION DISORDERS AND DISEASES ASSOCIATED WITH LEPTIN PRODUCTION DISORDERS Expired - Lifetime FR2792837B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9905450A FR2792837B1 (en) 1999-04-29 1999-04-29 MEDICINES USEFUL FOR THE TREATMENT OF ADIPOSE MASS REGULATION DISORDERS AND DISEASES ASSOCIATED WITH LEPTIN PRODUCTION DISORDERS
PCT/FR2000/001171 WO2000066149A1 (en) 1999-04-29 2000-04-28 Medicines useful for treating disorders of regulation of body fatness and diseases related to disorders of leptin production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905450A FR2792837B1 (en) 1999-04-29 1999-04-29 MEDICINES USEFUL FOR THE TREATMENT OF ADIPOSE MASS REGULATION DISORDERS AND DISEASES ASSOCIATED WITH LEPTIN PRODUCTION DISORDERS

Publications (2)

Publication Number Publication Date
FR2792837A1 FR2792837A1 (en) 2000-11-03
FR2792837B1 true FR2792837B1 (en) 2001-07-13

Family

ID=9545027

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9905450A Expired - Lifetime FR2792837B1 (en) 1999-04-29 1999-04-29 MEDICINES USEFUL FOR THE TREATMENT OF ADIPOSE MASS REGULATION DISORDERS AND DISEASES ASSOCIATED WITH LEPTIN PRODUCTION DISORDERS

Country Status (2)

Country Link
FR (1) FR2792837B1 (en)
WO (1) WO2000066149A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CA2501946C (en) 2002-10-16 2014-12-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
WO2006013427A2 (en) * 2004-07-30 2006-02-09 Pfizer Products Inc. Treatment of ccr2 mediated diseases or disorders
US11701437B2 (en) 2017-05-12 2023-07-18 President And Fellows Of Harvard College Systemic delivery of polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897980A3 (en) * 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor

Also Published As

Publication number Publication date
WO2000066149A1 (en) 2000-11-09
FR2792837A1 (en) 2000-11-03

Similar Documents

Publication Publication Date Title
MA28689B1 (en) PYRROZOLOTRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
FR13C0060I2 (en) FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYLUREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS
YU37602A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
FR2777192B1 (en) HERBAL COMPOSITION FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES, BRONCHITIS AND RESPIRATORY DISORDERS AND PREPARATION METHOD THEREOF
NO963568D0 (en) Pharmaceutical composition for the treatment of blood coagulation disorders, methods for the preparation thereof and its use
MA26779A1 (en) 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS.
HK1042825A1 (en) Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
MA29084B1 (en) INDENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
LV11666A (en) Pharmaceutical preparations and medications for the treatment and treatment of endothelial disorders
MA26658A1 (en) VALEROHYDRAZINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES CONTAINING THEM, AND THEIR USE FOR PREPARING SUCH A MEDICINAL PRODUCT
IL119459A0 (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
FR2792837B1 (en) MEDICINES USEFUL FOR THE TREATMENT OF ADIPOSE MASS REGULATION DISORDERS AND DISEASES ASSOCIATED WITH LEPTIN PRODUCTION DISORDERS
FR2717080B1 (en) Use of eipriprodil and its enantiomers for the preparation of medicaments useful in the treatment of peripheral neuropathies and central neurodegenerative diseases.
MA26683A1 (en) PIPERIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND PHYSIOLOGICAL DISORDERS
FR2792199B3 (en) USE OF OSANETANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OF MOOD DISORDERS
DZ3225A1 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF LUNG DISEASES
ITRM960827A0 (en) MEDICINAL PRODUCT FOR THE THERAPEUTIC TREATMENT OF AGE-RELATED MACULOPATHY, NON-AGE-RELATED MACULOPATHY AND FOR PROPHYLAXIS
FR2619713B1 (en) APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN MEDICINE FOR THE TREATMENT OF SLEEP AND DEPRESSION DISORDERS
MA22278A1 (en) PROCESS FOR THE TREATMENT OF RESPIRATORY DISORDERS
HUP0301831A2 (en) Use of bioactive metabolites of gepirone for the treatment of psychological disorders
FR2774289B1 (en) MEDICINE FOR THE TREATMENT OF APOPTOSIS DISORDERS
NO990450L (en) Treatment of mental disorders
MA26652A1 (en) MIXED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKLETAL WEAKNESS, AND METHOD FOR THEIR PREPARATION
FR2718024B1 (en) Medicine and pharmaceutical composition for the treatment of inflammation.
MA26908A1 (en) S-METHYL-DIHYDRO-ZIPRASIDONE FOR THE TREATMENT OF PSYCHIATRIC AND EYE DISORDERS

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20